ARTICLE | Clinical News
Ralfinamide: Phase IIb/III data
May 10, 2010 7:00 AM UTC
Top-line data from the double-blind, international Phase IIb/III SERENA trial in 411 patients showed that ralfinamide missed the primary endpoint of significantly reducing pain intensity as measured b...